NCT06808932View on ClinicalTrials.gov

VK4-116 Phase I Study With Food-Effect

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

May 30, 2026

Study Completion Date

June 30, 2026

Conditions
Opioid DependenceOpioid Use Disorder (OUD)
Interventions
DRUG

VK4-116

D3R antagonist

DRUG

Placebo

Each of the four dose groups of n=8 participants will be assigned to active drug or placebo in the ration 6:2.

Trial Locations (1)

66212

Altasciences Clinical Kansas, Overland Park

All Listed Sponsors
collaborator

Altasciences Company Inc.

INDUSTRY

lead

National Institute on Drug Abuse (NIDA)

NIH